Medications that influence appetite and metabolic regulation — such as GLP-1 receptor agonists (e.g., Ozempic, Wegovy) — are becoming increasingly common in weight and metabolic care.

Newer agents, including investigational medications like retatrutide (a triple hormone agonist currently in clinical trials), are also attracting attention due to their significant effects on appetite and body weight.

For some individuals, these medications can meaningfully reduce appetite, improve blood sugar regulation, and support weight loss.

However, like any intervention that alters physiology, they work best when paired with a thoughtful plan that protects muscle, energy, and long-term metabolic health.

This article is not about being for or against these medications. It’s about understanding how to support your body properly if you are using them.

How These Medications Work

GLP-1 receptor agonists mimic the hormone glucagon-like peptide-1, which plays a role in:

• Appetite regulation

• Slowing gastric emptying

• Blood sugar control

• Increasing satiety

Retatrutide and similar investigational agents act on multiple hormonal pathways (GLP-1, GIP, and glucagon receptors), amplifying effects on appetite and metabolic signalling.

The result for many people is a significant reduction in hunger and overall intake.

While this can support weight loss, appetite suppression creates important nutritional considerations.

Weight Loss vs. Muscle Loss

Weight loss is not the same as fat loss.

When total intake drops — particularly protein intake — the body may lose lean muscle tissue alongside fat mass.

This matters because muscle is:

• A major contributor to metabolic rate

• Protective against insulin resistance

• Critical for strength and ageing well

• Important for long-term weight maintenance

Rapid appetite reduction without intentional protein planning can increase the risk of losing valuable lean mass.

Appetite Suppression and Under-Fuelling

Common experiences while using GLP-1 medications or investigational appetite-modulating agents include:

• Reduced hunger

• Eating smaller portions

• Feeling full quickly

• Occasional nausea or digestive discomfort

While reduced appetite may feel like progress, consistently under-fuelling can contribute to:

• Fatigue

• Reduced training capacity

• Hormonal disruption

• Micronutrient deficiencies

• Increased physiological stress

Supporting the body during this phase is essential.

What Proper Support Should Focus On

If you are using a GLP-1 medication — or participating in clinical use of newer agents like retatrutide — nutrition strategy shifts from simply “eating less” to eating intentionally.

Key priorities include:

• Preserving lean muscle mass through adequate protein intake

• Maintaining micronutrient sufficiency despite reduced volume

• Supporting energy levels and performance

• Managing digestive side effects

• Monitoring strength and functional capacity

• Planning for sustainability — whether continuing medication long-term or transitioning off

The goal is not just weight change, but metabolic resilience.

The Bigger Picture: Long-Term Health

Medications that influence appetite can be powerful tools. But they do not replace foundational principles:

• Muscle preservation

• Nervous system regulation

• Sustainable eating patterns

• Resistance training and movement

• Clear, realistic habit systems

Whether someone remains on medication or eventually discontinues it, the long-term outcomes are shaped by how well muscle, metabolism, and daily habits are protected during the process.

A Balanced Perspective

For some individuals, GLP-1 medications or emerging agents like retatrutide may play a meaningful role in improving metabolic markers and reducing health risks.

For others, different approaches may be appropriate.

Both decisions deserve thoughtful support rather than judgement.

If you are currently using one of these medications and want to ensure your nutrition supports muscle, energy, and long-term wellbeing, a structured, personalised plan can help protect what matters most.

Health is rarely about extremes. It’s about moving forward in a way that preserves strength, resilience, and clarity.

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and investigational agents like retatrutide have reshaped metabolic care. They can reduce appetite, improve blood sugar control, and support significant weight loss.

But what happens when you stop?

This isn’t about being for or against these medications. It’s about understanding the physiology so you can protect long-term health.

Appetite Often Returns

These medications work by amplifying satiety signalling. When they are withdrawn, appetite typically increases again.

This isn’t a failure. It’s biology.

If structured eating habits and muscle preservation were built during treatment, the transition may feel manageable. If not, the return of hunger can feel abrupt.

What the Research Shows

A recent systematic review in The BMJ examined weight regain after stopping weight-management medications, including GLP-1 receptor agonists.

Key findings:

• Weight regain averaged around 0.4 kg per month after discontinuation.

• Many individuals were projected to return to pre-treatment weight within about 1.7 years.

• Improvements in blood pressure, cholesterol, and glycaemic markers often moved back toward baseline within roughly 1.4 years.

• Weight regain occurred faster than after behavioural interventions alone.

This doesn’t mean medications don’t work. It means that once the pharmacological appetite suppression stops, underlying physiological drivers re-emerge.

Metabolic Rate and Muscle

Stopping GLP-1 medications does not “damage” metabolism. But metabolism adapts during weight loss.

Resting metabolic rate is influenced by:

• Body size

• Lean muscle mass

• Hormonal environment

• Energy intake

If significant weight loss occurred — especially with loss of lean mass — resting energy expenditure may be lower simply because the body is smaller and potentially carrying less muscle.

Muscle preservation during treatment is one of the most important predictors of smoother long-term outcomes.

The Risk of Rebound

Weight regain after discontinuation is not about willpower. It reflects:

• Appetite returning

• Energy intake increasing

• Adaptive metabolic changes

• Previous eating patterns resurfacing

If structured nutrition, resistance training, and sustainable habits were not developed during treatment, the body often trends back toward its previous set point.

Why Muscle Matters

Muscle supports:

• Metabolic rate

• Insulin sensitivity

• Strength and functional capacity

• Long-term weight maintenance

Low protein intake and minimal resistance training during appetite suppression increase the risk of losing lean tissue. That makes maintenance harder later.

A Window of Opportunity

These medications can create a useful window:

• Reduced appetite

• Improved metabolic markers

• Space to implement new habits

If that window is used to prioritise protein, preserve muscle, stabilise eating patterns, and manage stress, long-term outcomes improve significantly.

If the medication does all the work, the body often reverts once it’s removed.

A Balanced Perspective

GLP-1 medications and emerging agents like retatrutide can be valuable tools for some individuals. But long-term metabolic health depends on more than appetite suppression.

It depends on:

• Muscle preservation

• Structured eating patterns

• Resistance training

• Stress regulation

• Sustainable habits

Stopping medication doesn’t break your metabolism. It reveals what was built — or not built — underneath.

The more foundations you lay during treatment, the smoother the transition will be.